Tannin Specific Natural Extract for COVID-19 Infection (TanCOVID)
COVID-19, SARS-CoV 2, Coronavirus Infection
About this trial
This is an interventional treatment trial for COVID-19
Eligibility Criteria
Inclusion Criteria:
- Over 18 years of age hospitalized in the general hospitalization room, who meet the definition of "Confirmed case COVID-19" (https://www.argentina.gob.ar/salud/coronavirus-COVID-19/definicion -of-case)
Exclusion Criteria:
- Pregnancy
- Lactancy
- Hypersensitivity to polyphenols
- Patients unable to receive oral medication (severe cognitive impairment, assisted ventilation, impaired state of consciousness)
- Lack of consent
- Participation in any other interventional clinical trial
Sites / Locations
- Hospital de Clinicas
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
TREATED
CONTROL
Participants will receive a supply of 28 -- 390 mg ARBOX capsules for 14 days. Patients will be supplemented with 2 capsules of ARBOX per day and standard therapy. Standard treatment includes: Antipyretics or Lopinavir / Ritonavir, Azithromycin and Hydroxychloroquine, as appropriate (treatment currently recommended by the department of Infectious Diseases of the Hospital de Clínicas that could undergo to modifications). In addition, if necessary: supplemental O2, non-invasive ventilation, antibiotic therapy.
Participants will receive placebo supply for 14 days. The placebo will be administrated with the identical dose as described for the test product. Beside patients will receive the standard theraphy, which includes Antipyretics or Lopinavir / Ritonavir, Azithromycin and Hydroxychloroquine, as appropriate (treatment currently recommended by the department of Infectious Diseases of the Hospital de Clínicas that could undergo to modifications). In addition, if necessary: supplemental O2, non-invasive ventilation, antibiotic therapy.